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Background: The human epidermal growth factor receptor-2 (HER-2) expression level is a critical element for
determining the prognosis and management of breast cancer. HER-2 targeted therapy in breast cancer depends
on the reliable assessment of HER-2 expression status but current standard methods are lacking a rigorous quantitative
assay. To address this challenge, we developed an assessment of HER-2 expression method by well-based reverse
phase protein array (RPPA).
Results: Well-based RPPA is based on a robust protein isolation methodology paired with a novel
electrochemiluminescence detection system. HER-2 value of well-based RPPA significantly correlated with dot
blotting results (R2 = 0.939). By well-based RPPA, we successfully detected HER-2 expression in 76 human breast
formalin-fixed paraffin-embedded tissue samples. We observed 93.4% (71/76) concordance between well-based
RPPA and current HER-2 immunohistochemical assessment guideline. When the cutoff level of HER-2 value was
set to 0.689 (HER-2/GAPDH) on the basis of receiver-operating characteristic curve, the area under the curve
was 0.975 (95% CI, 0.941-1.000). Sensitivity and specificity of well-based RPPA was 92.1% and 94.7%, respectively.
Conclusions: HER-2 value by well-based RPPA was correlated with the current HER-2 status guideline, suggesting that
this normalized HER-2 assessment may offer advantages over unnormalized current immunohistochemical assessment
methods.
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Human epidermal growth factor receptor-2 (HER-2), a
proto-oncogene, encodes a tyrosine kinase receptor that
functions to regulate cell growth, differentiation and sur-
vival [1,2]. In malignant cells, overexpression of the
HER-2 protein by HER-2 gene amplification, leads to
tumor development in 25-30% of invasive breast cancers
and is associated with poor prognosis and shortened sur-
vival [3]. Furthermore, HER-2 is known to play an import-
ant role in patient selection of trastuzumab (Herceptin™®),
a monoclonal antibody drug targeting the HER-2 protein* Correspondence: genejock@helix.nih.gov
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unless otherwise stated.[4-6]. In particular, 1 year treatment of trastuzumab after
adjuvant therapy has shown to significantly improve
disease-free survival for HER-2 positive breast cancer
patients [6].
Determining the “optimized” method of detecting HER-2
overexpression remains controversial. The American
Society of Clinical Oncology/College of the American
Pathologists (ASCO/CAP) recommend using immuno-
histochemistry (IHC) and reflex testing of equivocal re-
sults by in situ hybridization (ISH) [7]. IHC is a simple
and fast method that detects HER-2 protein expression
on the cell surface by an antibody, and overexpression
is based on HercepTest™ (DAKO, Glostrup, Denmark)
or other assays and interpreted as scores of 0 and 1+ as
negative and 2+ and 3+ as positive. IHC 3+ scores ared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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equivocal and require further assessment by fluores-
cence in situ hybridization (FISH) [8]. While both
methods are highly specific and reproducible when
performed under standardized and validated conditions,
IHC is semiquantative and staining interpretation is
variable and subjective [9,10]. Pre-analytic variables in
the fixation and processing of breast specimens are well
described to undermine HER-2 results. On the other
hand, FISH assay requires expensive and technically
difficult instrumentation [11]. In addition, the Food and
Drug Administration (FDA) has approved chromogenic
in situ hybridization (CISH, Spot-Light CISH) and ISH
(Dual ISH) techniques for the evaluation of the amplifi-
cation of the HER-2 gene, which do offer the precision
of the FISH testing but on the morphometric evaluation
of histological slides. However, this test is expensive
and challenging to perform and interpret.
Reverse phase protein array (RPPA) is a sensitive and
high throughput technology that allows the quantification
of given makers in small amount of protein from
biological specimens including formalin-fixed paraffin-
embedded (FFPE) tissues [12]. This technique involves
arraying protein samples on the substrate and then
probing with the appropriate antibody, thus allowing
various samples to be analyzed at the same time. How-
ever, current RPPA platforms require sophisticated
printers and complicated study designs. To overcome
these obstacles, we developed a well-based RPPA and
showed the possibility as a powerful tool for proteomic
profiling in clinical studies [13]. This platform does not
require an arrayer and utilizes an electrochemilumines-
cence detection system.
In order to evaluate the benefits of well-based RPPA in
HER-2 assessment, we extracted protein from 76 human
breast cancer FFPE tissues and subsequently we per-
formed a prospective study comparing HER-2 determin-
ation with IHC and well-based RPPA. We demonstrated
that well-based RPPA effectively measured the negative
and positive expression levels of HER-2 in breast FFPE
tissue. This quantitative proteomic method is a powerful
and reliable tool and can be used as an adjunct or as an
alternative to IHC for optimal patient evaluation.
Results
Evaluation of HER-2 status by IHC completed FISH
Patients age ranged from 32 to 94 years (mean 49 years).
Of the 76 patients, 54 cases were ductal carcinoma and 21
were lobular carcinoma. Representative images of HER-2
immunohistochemical staining are showed in Figure 1. In
the semiquantitative analysis of HER-2 protein expression,
the score was 0 in 10 cases (13.2%), 1+ in 22 (28.9%), 2+
in 15 (19.7%), and 3+ in 29 (38.2%), respectively. According
to ASCO/CAP HER-2 scoring guideline, we performedFISH analysis for all IHC score 2+. Among the 15 equivocal
cases, 9 were finally scored positive amplified by the overall
HER-2 status, 6 cases were nonamplified.
Quality validation of extracted protein from FFPE tissue
To assess immunoreactive protein quality, we extracted
protein from 10 archival human breast FFPE tissue speci-
mens and subsequently performed dot blotting. Proteins
extracted from archival human breast FFPE tissue speci-
mens contained high amounts of immunoreactive proteins
for HER-2 and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Figure 2A). HER-2 expression was detected
only in the HER-2 positive samples (2+ and 3+ score
based on IHC) whereas GAPDH signal was shown in all
tested samples. With the immunoreactive proteins, we an-
alyzed whether the expressional signals from dot blotting
analysis correlated with data from well-based RPPA.
Relative HER-2 signals in series of breast FFPE tissue
specimens were measured and the ratio of HER-2 to
GAPDH was calculated. As shown in Figure 2B & C,
the signals in well-based RPPA correlated with that of
dot blotting analysis (R2 = 0.939), and had greater
sensitivity.
Evaluation of well-based RPPA methodology
In order to evaluate diagnostic value of well-based RPPA,
we investigated HER-2 status on all 76 cases and the result
compared to the current guideline. By well-based RPPA,
the HER-2 expression levels differed significantly be-
tween tested subgroup (0/1+ vs. 3+, P < 0.001; 2+ vs. 3+,
P = 0.001). However, there was no significant difference
between 0/1+ and 2+ subgroups (Figure 3A). Subse-
quently, we further analyzed equivocal group which are
determined 2+ specimens by current immunochemical
assessments. Notably, there is significant difference be-
tween FISH negative and FISH positive cases by well-
based RPPA (Figure 3B, P = 0.012).
Next we evaluated the diagnostic performance of well-
based RPPA to determine HER-2 expression status.
Figure 4A shows the ROC curve for the discrimination
HER-2 expression status with positive vs. negative. The
area under the curve (AUC) of well-based RPPA was
found to be 0.975 (95% CI, 0.941 -1.000). A cutoff value of
0.689 (ratio of HER-2/GAPDH) had the highest accuracy
(minimal false negative and false positive results) for
HER-2 detection. Figure 4B shows the individual relative
HER-2 value in the different IHC groups. Concordance
was excellent in 0/1+ subgroup (93.8%) and 3+ group
(93.1%). In addition, the well-based RPPA technology was
showed great concordance (93.3%) with FISH in IHC 2+
subgroup whereas IHC showed lower agreement (60%,
9/15). Overall, the well-based RPPA showed great sensi-
tivity and specificity, especially this methodology could be
used substantial HER-2 expression status confirmation
Figure 1 Representative immunohistochemical staining images of HER-2. The expression of HER-2 protein was detected by IHC. Representative
HER-2 expression shown with 0 (A), 1+ (B), 2+ (C) and 3+ (D) subgroups. Scale bar: 100 μm.
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(94.6%) (Table 1).
Discussion
The accurate assessment of HER-2 in breast cancer is an
imperative issue because HER-2 status is essential for
identifying cancer patients who are appropriate for treat-
ment with the anti-HER-2 humanized monoclonal anti-
body trastuzumab. Approximately 1.4% of patients who
receive trastuzumab as a single agent [5,14,15] experience
cardiotoxic side effects and this percentage increases when
trastuzumab is combined with other chemotherapies (13%
with paclitaxel and 27% with anthracyclines, respectively)
[16], along with the cost of receiving therapy. Currently,0 0 0 1 1










































Figure 2 Comparison of HER-2 expression levels by well-based RPPA
tissues. Protein extracted from 10 FFPE breast cancer tissue specimens and su
The membrane was hybridized with HER-2 and GAPDH probes. HER-2 expres
GAPDH detected in all tested samples. Relative HER-2 expressional signals we
signals from four different IHC score subgroups were measured using we
well-based RPPA and dot blotting, respectively. The bar graph shows the aver
RPPA and dot blotting was strongly correlated for HER-2 expression status (R2the assessment of HER-2 status is performed predomin-
antly by IHC with further validation being performed by
FISH in the clinical laboratory.
IHC method measures the expression of the HER-2 pro-
tein on the surface of the tumor cells while FISH test mea-
sures the amplification of the HER-2 gene present in the
cells. The wide range of concordance rates between HER-2
protein expression by IHC and HER-2 gene amplification
by FISH has been well documented in several studies. In
addition, IHC by comparison to FISH showed 21.8%
false-positive rate and 8.9% false-negative rate at local
laboratories [17]. The discordance between IHC and
FISH assessment of HER-2 status in breast cancer reflects
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and dot blotting. (A) Dot blotting of HER-2 in breast cancer FFPE
bsequently a total of 10 μg protein spotted on nictrocellulose membrane.
sion signals were only detected in 2+ and 3+ positive samples whereas
re calculated the ratio of HER-2/GAPDH. (B) Relative HER-2 expressional
ll-based RPPA technology. Gray and white bars represent results of
age ± SD of three replicated wells. (C) The signals from the well-based
= 0.939).


































































































Figure 3 Assessment of HER-2 expression status by well-based RPPA in human breast FFPE tissue specimens. (A) Cases with 3+ score
had significantly higher HER-2 expression than those with 0/1+ (P < 0.001) and 2+ score (P = 0.001). However, there is no significant difference between
0/1+ and 2+ subgroups (P = 0.837). (B) Tumor specimens with FISH positive showed significantly high HER-2 expressional values compare with that of
FISH negative (mean of 1.233 versus 0.407, P = 0.012) in IHC 2+ subgroup. Relative HER-2 expressional signals were calculated the ratio of HER-2/GAPDH
and the value expressed as box plot.
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though the HercepTest is accurate and reproducible than
laboratory developed test, the assessment of HER-2 by
IHC is highly dependent upon both preanalytic factors
and analytic factors [18,19]. For these reasons, several
methods for the evaluation of the HER-2 status have been























Figure 4 HER-2 ROC curve and levels in breast cancer specimens. (A)
HER-2 postive and negative cases. (B) Individual HER-2 expression levels sh
(●) and negative (○) were categorized according to the current ASCO/CAPslot blot, dot blot analysis, polymerase chain reaction,
chromogenic in situ hybridization and immunoassay
[20-26]. Many of these approaches focused on exploration
at the gene expression level, and frequently require special
instrumentation, technical expertise and can be time
consuming. In addition, these methods did not employ a





















































ROC curve for well-based RPPA assay results in distinguishing between
owed in 0/1+ (n = 32), 2+ (n = 15) and 3+ (n = 29) subgroups. Positive
guideline. A value of cutoff was 0.0689.










IHC 100 84.2 86.4 100
Well-based
RPPA
92.1 94.7 94.6 92.3
Abbreviations: IHC, immunohistochemistry; Well-based RPPA, well-based
reverse phase protein array; PPV, positive predictive value; NPV, negative
predictive value.
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approaches. Thus our methodology has an advantage that
can evaluate HER-2 value without risk of low reliability
and poor validity in the current immunohistochemical
HER-2 assessment.
Notably, patients with high HER-2 expression at the 3+
by IHC showed approximately 35% (95% CI, 24.4-44.7%)
response rate in randomized phase II study [5]. In this
circumstance, there is a need for an accurate quantitative
method to assess HER-2 protein expression using FFPE
which can be performed in a clinical pathology setting. In
this study, we propose that the use of this technology in
HER-2 protein profiling can lead to fast and more reliable
quantitative analysis. In order to successfully compare and
justify implementation of this novel assay in accordance
with approved clinical methods, we investigated the re-
sults from well-based RPPA in correlation with those of
IHC and FISH data. Our study shows a high level of
correlation between ASCO/CAP guideline and well-based
RPPA (93.4%). Of particular interest were the 15 cases that
were classified as 2+ when assessed using IHC. Six of the
cases were considered to be positive by well-based RPPA
and the remaining nine cases were negative. Only 2 out of
the 15 would be considered borderline by well-based
RPPA with a value of between 0.631 - 0.690 (HER-2/
GAPDH). Therefore utilizing this protein array method-
ology as an adjunct to IHC would reduce the number of
cases requiring further testing by FISH by 86.6%. Current
tests that use inadequate post-surgical archival tissue
specimens can compromise the accuracy of HER-2 sta-
tus in a patient’s tumor such as fixation and preserva-
tion [27] and also observer variability due to tumor
heterogeneity [28]. Although both aspects of variation
can be addressed, the risks for false-positive and nega-
tive results are still prevalent.
The reverse phase protein array (RPPA) is a high-
throughput technology which is suitable for monitoring
changes in protein expression between disease and non-
disease states [12]. In original RPPA technology, each lys-
ate is arrayed in triplicates on nitrocellulose-coated slides
in a dilution curve [29]. However, this approach is not
compatible for large numbers of samples due to complex-
ity of array printing and managing. In order to overcome
these disadvantages, this platform was recently upgradedto a calibrated assay format like to ELISA [30]. Although
this platform allows a single concentration printing in-
stead of serial dilution of each lysate, this platform is also
needs additional serial diluted reference panel which con-
tain differing amounts of the target molecules, as well as
high and low controls per each slide or matrix. Recently,
Berg et al. reported a successful HER-2 assessment from
35 core biopsies and surgical specimens using RPPA, the
authors tested only cancer cell rich tissue specimens
(at least over 85% cancer cell) [31]. In addition, Wulfkuhle
et al. demonstrated that HER-2 value by RPPA is concord-
ant with FISH and/or IHC data [32]. Like RPPA, this
well-based protein array methodology has the ability to
quantify the levels of protein expression in a truly
quantitative and continuous manner. Previously, we re-
ported a successful protein extraction from FFPE tissue
[13]. Our method has great protein extraction yield
from relatively small amounts of material, with rela-
tively low concentration of detergent regardless of the
deparaffinization step. Prior to use of an antibody in
well-based RPPA, its specificity was validated by dot
blot (Figure 2). It should be noted that the well-based
RPPA used 25 fold less protein than the dot blot.
Subsequently, HER-2 assay by well-based RPPA sit in
the linear dynamic range (data not shown). Finally, the
HER-2 signal was normalized to GAPDH protein, similar
to western blotting. Our assay showed a high specificity of
94.7% than classical IHC analysis of 84.2%. While the
sensitivity was lower than IHC, the results may reflect
potential false positives commonly seen in IHC.
Basically, our well-based RPPA does not require the use
of a printer arrayer, nor does it use scoring a dilution
curve. Furthermore, one substantial advantage is the cap-
acity to measure multiple proteins and develop a normal-
ized metric based on expression of a largely invariant
protein. For the best results, the researcher should be
checking the dynamic range against the target molecule,
using antibody which have great specificity and sensitivity
prior to the real experiment. As most of proteomic assay,
this methodology is also mainly depending on the anti-
body quality.
HER-2 status can be assessed on both surgical speci-
mens and core biopsies by IHC and FISH. These both
methodologies can be influenced by pre-analytical factors
including warm ischemia, fixation time and tissue process-
ing conditions. We suppose the assay quality of well-based
RPPA is also partially linked with pre-analytical variables.
However, the pre-analytical variables are less impactful on
the result of this new methodology because the new array
is very sensitive and specific assay, as well normalizing for
cellular content and pre-analytic factors that impact tissue
quality.
The protein quality of FFPE tissue shows a “smear” on
SDS-PAGE and the extent of smearing represents the
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different degradation levels for each tissue samples. This
means the total protein alone is not an appropriate
normalization tool in the FFPE tissue samples. In a previ-
ous study, we showed that GAPDH protein signal is a
good indicator as an internal control to measure the pro-
tein quality from each tissue sample [33]. Thus, we calcu-
lated the HER-2 signal based on double normalization
with total amount of protein and the GAPDH signal. This
approach has an advantage that can evaluate HER-2 value
without risk of low reliability.
Conclusions
In summary, we have demonstrated the use and applic-
ability of a well-based RPPA for HER-2 detection and
quantification with normalization. The comparative data
analysis between well-based RPPA and FISH were highly
correlated in the equivocal subgroup indicating well-based
RPPA would be more useful in predicting anti-HER2 ther-
apy in patient clinical management. Additional evaluation
is required, optimally with breast cancer cases that re-
ceived Herceptin, to determine if this approach can out-
perform the current IHC based method, which has a weak
positive predictive value in identification of patients who
will respond to Herceptin treatment.
Materials and methods
Tissue specimens
A total of 76 formalin-fixed, paraffin-embedded (FFPE)
breast cancer specimens were obtained from the collec-
tion of the Tissue Array Research Program (TARP), Be-
thesda, MD and anonymized breast cancer tissue samples
of the laboratory of Pathology at RWTH Aachen
University, Aachen, Germany. Material was obtained
with appropriate human protection approvals from the
institutional review board of the RWTH Aachen uni-
versity hospital and Office of Human Subjects Research
at the NIH.
Immunohistochemistry
Breast cancer specimens were assessed for HER-2 status
using a DAKO autoimmunostainer (DAKO, Carpinteria,
CA). Briefly, whole sections (5 μm) were deparaffinized
with xylene and rehydrated through graded alcohols to
distilled water. Endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide for 10 minutes,
and antigens were retrieved for 40 minutes in 10 mmol/L
citrate buffer, pH 6.0, with steamer. The whole section
slides were incubated with the rabbit anti-human HER-2
polyclonal antibody A0485 (1:500 dilution; DAKO) for
30 minutes at 25°C. Slides were then incubated with a
DAKO Envision+ for 30 minutes at 25°C, subsequently
reacted with 3,3′-diaminobenzidine as a chromogen sub-
strate for 3 minutes, counterstained using a ModifiedHarris hematoxylin (Thermo Scientific, Rockford, IL) and
coverslipped after dehydration.IHC interpretation and scoring
All IHC cases were digitized utilizing at 20× magnification
using an Aperio CS scanner (Vista, CA) and the images
were reviewed in SlidePath software (Leica, Buffalo Grove,
IL). The reviewers adhered to the ASCO/CAP guidelines
for HER-2 interpretation of invasive breast cancer.
Therefore, all cases were classified as one of the following;
0, no staining observed, or membrane staining observed
in < 10% of tumor cells; 1+, a faint/barely perceptible
membrane staining is detected in ≥ 10% of tumor cells, the
cells exhibit incomplete membrane staining; 2+, a weak to
moderate complete membrane stain is observed in ≥ 10%
of tumor cells; 3+, a strong complete membrane staining
is observed in ≥ 10% of tumor cells.Fluorescence in situ hybridization
Of all the cases classified by IHC as HER-2/neu 2+,
FISH analysis was performed. For fluorescence in situ
hybridization (FISH), the PathVysion kit by Abbott was
used (02 J01-035, Abbott Laboratories, Abbott Park, IL).
As used for IHC, 5 μm sections of paraffin blocks were
processed following manufacturers guidelines (deparaffi-
nation, rehydration, pretreatment, enzyme treatment,
fixation, hybridization of probes, DAPI counterstain,
coverslipping). Two probes are included in the kit, one
probe against the HER-2/neu locus, 17q11.2-q12 LSI,
fluorescent to SpecOrange, the second probe against
centromer of chromosome 17 (CEP17), fluorescent to
SpecGreen. In 20 cells, both signals were counted of
each nucleus followed by building a ratio (HER-2/neu to
CEP17) of the sums of signals. Below a ratio of 2, HER-2/
neu was considered not amplified, a ratio of 2 and up was
considered amplified. The analysis was performed on an
inverse microscope by Zeiss, Axiovert 100 using Zeiss fluor-
escent filter sets for both probes (Zeiss, Thornwood, NY).Protein extraction
Protein extraction from archival FFPE tissue was per-
formed as previously described [13]. Briefly, two 10 μm
sections of each specimen were lysed with an extraction
buffer [1x high pH Antigen retrieval buffer (DAKO),
1% NaN3, 1% SDS, 10% glycerol, and protease inhibitor
(1 tablet/25 ml, Roche, Basel, Switzerland)]. Afterwards,
incubation for 15 mins at 115°C within a pressure
cooker followed by microcentrifugation at 13000 rpm
for 30 mins at 4°C. Protein was stored −20°C until fur-
ther use. Protein concentrations were determined using
BCA protein assay (Pierce Biotechnology, Rockford, IL)
and used according to the manufacturer’s instructions.
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The protein lysates (10 μg) extracted from human breast
FFPE tissue sections was dotted to 0.2 μm nitrocellulose
membrane using Bio-Dot Microfiltration Apparatus (Bio-
Rad, Hercules, CA). The membranes were blocked in 5%
nonfat dry milk in TTBS (50 mM Tris, 150 mM NaCl,
0.05% Tween 20, pH 7.5) for 1 hour at room temperature
(RT), washed, and then incubated overnight in 5% BSA in
TTBS at 4°C containing antibodies; HER-2 polyclonal
antibody (DAKO, 1:2000) and anti-GAPDH (Calbiochem,
Gibbstown, NJ, 1:1000). Subsequently, the membranes
were washed and incubated with horseradish peroxid-
ase labeled anti-rabbit and anti-mouse secondary anti-
body for 90 minutes and enhanced using a SuperSignal
Chemiluminescence kit (Pierce Biotechnology) and de-
tected on Kodak Biomax MR X-ray film (Kodak).Well-based reverse phase protein array
In order to quantitate HER-2 expression values, we per-
formed well-based reverse phase protein array (RPPA) as
previously reported [13]. Briefly, extracted proteins
(400 ng) were applied onto 96-well Multi-Spot™ plates
(Meso Scale Discovery, Gaithersburg, MD, MA2400 96
HB Plate), the plate was allowed to dry at RT, and if
needed, further incubated at 37°C for 30 min. The
antigen-coated plates were pre-incubated with 5% BSA
in PBST for 60 min at RT before primary antibody incuba-
tion. Anti-HER-2 (DAKO) and anti-GAPDH (Calbiochem)
were diluted 1:1000 and 1:5000 with 5% BSA in PBST,
followed overnight incubation at 4°C. After washing with
PBST, the plates were incubated for 90 min with goat anti-
rabbit or mouse SULFO-TAG™ antibodies (Meso Scale
Discovery) at a dilution of 1:2000. The plates were washed
three times with PBST. MSD-T read buffer was added to
the plates and signals were detected using Sector Imager
2400 reader (Meso Scale Discovery). BSA coated wells were
included on each plate as a control of non-specific binding.
HER-2 expression signal was normalized with the value of
GAPDH.Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics
19.0 (SPSS Inc., Chicago, IL). Comparison of means among
the three groups (0/1+, 2+ and 3+) was performed using
one-way ANOVA post hoc test. The accuracy of well-based
RPPA for determination of HER-2 positive or negative
breast cancer tissue samples was evaluated using receiver-
operating characteristic (ROC) curve. Sensitivity, specificity,
positive predictive values (PPVs), negative predictive values
(NPVs) and their corresponding confidence intervals (CIs)
were calculated. A P-value < 0.05 was considered as statisti-
cally significant.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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